Foghorn Therapeutics (FHTX) Research & Development (2019 - 2026)

Foghorn Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• In Q1 2026, Research & Development fell 15.57% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $82.1 million (down 9.4% YoY), while the FY2025 annual figure was $85.5 million, down 9.59% from the prior year.
• Research & Development for Q1 2026 stood at $18.3 million, down from $22.0 million in the prior quarter.
• The five-year high for Research & Development was $30.0 million in Q1 2023, with the low at $18.3 million in Q1 2026.
• The 5-year median for Research & Development is $24.5 million (2022), against an average of $24.3 million.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 39.33% in 2022, then decreased 18.98% in 2025.
• Foghorn Therapeutics' Research & Development stood at $28.2 million in 2022, then retreated by 14.19% to $24.2 million in 2023, then decreased by 15.27% to $20.5 million in 2024, then grew by 7.5% to $22.0 million in 2025, then declined by 17.18% to $18.3 million in 2026.
• Business Quant data shows FHTX's Research & Development at $18.3 million in Q1 2026, $22.0 million in Q4 2025, and $20.0 million in Q3 2025.